Post-Conference Workshop Day

Thursday, September 9

Workshop A | 10.00 – 12.00 EST

Exploring RNA-based Therapeutics to Better Understand Tumor Microenvironment, Drug Delivery, and Cancer Vaccine Development

Session Objective: Attendees of this session will develop a greater understanding of how the tumor microenvironment can be modulated with RNA-based medicines based on previous cancer vaccine development work. Additionally, the workshop will cover a range of different cancers to draw comparisons between the key factors needed in vaccine development, appropriate combination therapies, and the effective role nanoparticle-based delivery plays in cancer immunotherapy.

This workshop will discuss:

  • RNAi delivery to regulate cancer and modulate its microenvironment
  • Development of several peptide- and siRNA- based vaccines for melanoma
  • Development of Vaccines for glioblastoma, CRC, PDAC, and breast cancer
  • Development of a novel nanoparticle based therapeutic vaccine for breast cancer immunotherapy

Workshop Leaders

Ronit Satchi Fainaro
Helena

Ronit Satchi-Fainaro
Head, Cancer Research and Nanomedicine Laboratory
Tel Aviv University

Helena Florindo
Group Leader, BioNanoSciences – Drug Delivery and Immunotherapy,
University of Lisbon

Lunch Break | 1.00 - 2.00 EST

Workshop B | 2.00 - 4.00 EST

Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient’s tumor and immune system

Session Objective: Attendees of this session will gain a greater understanding of personalized neoantigens relevant to both tumor and patient, and a uniquely identified immune suppressive class of proteins known as ‘inhibigens’ ™, which promote tumor growth and suppress immune anti-tumor effects. Additionally, the workshop will cover, from discovery to clinical trials, the development of a novel neoantigen vaccine, GEN-009, to treat a variety of tumors, optimized to the patient’s own T-cells.

This workshop will discuss:

  • Individualized immune responses against infectious and malignant pathogens and their interaction with their host
  • Neoantigens: Friend or Foe? Insights into tumor mutations and their ability
  • GEN-009:a highly immunogenic Neoantigen Vaccine. Insights into Phase1/2A

Workshop Leaders

Tom Davis
Jessica Flechtner
Hubert Lam

Tom Davis
Chief Executive Officer
Genocea Biosciences

Jessica Flechtner
Chief Scientific Officer
Genocea Biosciences

Hubert Lam
Director, Pre-clinical Development
Genocea Biosciences